@article{JTD2425,
author = {Ru Zhang and Lingli Tu and Lan Sun},
title = {Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge},
journal = {Journal of Thoracic Disease},
volume = {6},
number = {6},
year = {2014},
keywords = {},
abstract = {Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this review, we summarize the clinical evidence of TRBP and discuss the potential mechanisms to overcome TKI-acquired resistance.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/2425}
}